HCA, Ondine report low adverse events in phase 3 nasal photodisinfection trial
HCA Healthcare Research Institute and Ondine Biomedical presented interim Phase 3 LANTERN trial results at IDWeek 2026 showing a 0.31% treatment-related adverse event rate and strong patient tolerability. The findings could help support further evaluation of nasal photodisinfection as a pre-surgery infection-prevention tool.
Why it matters: - Surgical site infections remain a major risk in major operations, so any preoperative step that is both well tolerated and easy to repeat could affect infection-prevention workflows. - The interim safety data may help determine whether nasal photodisinfection can move closer to broader clinical use if efficacy results also hold up.
What happened: - HCA Healthcare Research Institute and Ondine Biomedical presented interim safety and patient-reported tolerability results from the Phase 3 LANTERN trial at IDWeek 2026 in Washington, DC. - The trial tested preoperative nasal photodisinfection in patients undergoing major surgery. - The study used Ondine’s non-antibiotic nasal photodisinfection technology, also known outside the U.S. as Steriwave® Nasal Photodisinfection.
The details: - The LANTERN trial enrolled 5,188 patients in a cluster-randomized crossover design. - The study ran across 18 hospitals, including 14 in the United States and four in Canada, from Dec. 27, 2024, to April 27, 2026. - Of 2,543 treated participants, eight had a treatment-related adverse event, for a rate of 0.31%. - All eight treatment-related adverse events were mild. - No serious adverse events were assessed as related to treatment. - Of 2,310 participants who completed the tolerability survey, 2,249, or 97.4%, described the two-minute procedure as “very bearable” or “bearable.” - Of 2,309 participants who answered the repeat-use question, 2,203, or 95.4%, said they were “very likely” or “likely” to undergo the procedure again if prescribed. - The interim findings remain subject to primary endpoint verification, prespecified analyses and database lock. - Final safety, efficacy and clinical outcome results will come after those steps are complete. - The trial compared preoperative nasal photodisinfection with the current standard of care. - The U.S. sites were 14 HCA hospitals, and the Canadian sites included Foothills, Rockyview, Royal Columbian and University of Alberta Hospitals.
Between the lines: - The unusually low adverse-event rate and high willingness to repeat the procedure suggest patients may accept the intervention in real-world surgical settings. - For a preoperative infection-prevention measure, tolerability matters because the intervention has to fit into busy surgical workflows and gain patient compliance. - The result is an interim readout, not a final verdict, so the biggest unanswered question is whether the safety profile will be matched by meaningful efficacy against surgical site infections.
What's next: - HCA Healthcare Research Institute and Ondine will complete primary analyses and database lock before releasing final trial results. - The companies said they will report final safety, efficacy and clinical outcome data after those steps. - Ondine will continue evaluating nasal photodisinfection in the Phase 3 LANTERN trial as the study advances.
The bottom line: - Early Phase 3 data suggest nasal photodisinfection was well tolerated in a large surgical population, but the trial still needs final efficacy results before the technology’s clinical value is clear.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Canadian Health Industry News
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.